journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

journal
https://www.readbyqxmd.com/read/30452337/adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-asco-clinical-practice-guideline-focused-update
#1
Harold J Burstein, Christina Lacchetti, Holly Anderson, Thomas A Buchholz, Nancy E Davidson, Karen A Gelmon, Sharon H Giordano, Clifford A Hudis, Alexander J Solky, Vered Stearns, Eric P Winer, Jennifer J Griggs
PURPOSE: To update the ASCO clinical practice guideline on adjuvant endocrine therapy based on emerging data about the optimal duration of aromatase inhibitor (AI) treatment. METHODS: ASCO conducted a systematic review of randomized clinical trials from 2012 to 2018. Guideline recommendations were based on the Panel's review of the evidence from six trials. RESULTS: The six included studies of AI treatment beyond 5 years of therapy demonstrated that extension of AI treatment was not associated with an overall survival advantage but was significantly associated with lower risks of breast cancer recurrence and contralateral breast cancer compared with placebo...
November 19, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30452336/phase-ii-trial-of-trastuzumab-and-docetaxel-in-patients-with-human-epidermal-growth-factor-receptor-2-positive-salivary-duct-carcinoma
#2
Hideaki Takahashi, Yuichiro Tada, Takashi Saotome, Kohei Akazawa, Hiroya Ojiri, Chihiro Fushimi, Tatsuo Masubuchi, Takashi Matsuki, Kaori Tani, Robert Y Osamura, Hideaki Hirai, Shuhei Yamada, Daisuke Kawakita, Kouki Miura, Shin-Etsu Kamata, Toshitaka Nagao
PURPOSE: Clinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease's rarity. We assessed the efficacy and toxicity of trastuzumab plus docetaxel in patients with locally advanced and/or recurrent or metastatic human epidermal growth factor receptor 2-positive SDC. PATIENTS AND METHODS: This was a single-center, single-arm, open-label, phase II study in Japan. The patients received trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks...
November 19, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30444686/defining-risk-factors-for-chemotherapeutic-intervention-in-infants-with-stage-4s-neuroblastoma-a-report-from-children-s-oncology-group-study-anbl0531
#3
Clare J Twist, Arlene Naranjo, Mary Lou Schmidt, Sheena C Tenney, Susan L Cohn, Holly J Meany, Peter Mattei, E Stanton Adkins, Hiroyuki Shimada, Wendy B London, Julie R Park, Katherine K Matthay, John M Maris
PURPOSE: Infants with stage 4S neuroblastoma usually have favorable outcomes with observation or minimal chemotherapy. However, young infants with symptoms secondary to massive hepatomegaly or with unfavorable tumor biology are at high risk of death. Our aim was to improve outcomes for patients with symptomatic and/or unfavorable biology 4S neuroblastoma with a uniform treatment approach using a biology- and response-based algorithm. PATIENTS AND METHODS: The subset of patients with 4S disease with MYCN-not amplified tumors with impaired or impending organ dysfunction, or with unfavorable histology and/or diploid DNA index, were eligible...
November 16, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30444685/select-a-phase-ii-trial-of-adjuvant-erlotinib-in-patients-with-resected-epidermal-growth-factor-receptor-mutant-non-small-cell-lung-cancer
#4
Nathan A Pennell, Joel W Neal, Jamie E Chaft, Christopher G Azzoli, Pasi A Jänne, Ramaswamy Govindan, Tracey L Evans, Daniel B Costa, Heather A Wakelee, Rebecca S Heist, Marc A Shapiro, Alona Muzikansky, Sudish Murthy, Michael Lanuti, Valerie W Rusch, Mark G Kris, Lecia V Sequist
PURPOSE: Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in patients with EGFR-mutant early-stage NSCLC. MATERIALS AND METHODS: In this open-label phase II trial, patients with resected stage IA to IIIA (7th edition of the American Joint Committee on Cancer staging system) EGFR-mutant NSCLC were treated with erlotinib 150 mg per day for 2 years after standard adjuvant chemotherapy with or without radiotherapy...
November 16, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30433852/bladder-preservation-with-twice-a-day-radiation-plus-fluorouracil-cisplatin-or-once-daily-radiation-plus-gemcitabine-for-muscle-invasive-bladder-cancer-nrg-rtog-0712-a-randomized-phase-ii-trial
#5
John J Coen, Peixin Zhang, Philip J Saylor, Cheryl T Lee, Chin-Lee Wu, William Parker, Timothy Lautenschlaeger, Anthony L Zietman, Jason A Efstathiou, Ashesh B Jani, Omer Kucuk, Luis Souhami, Joseph P Rodgers, Howard M Sandler, William U Shipley
PURPOSE: Fluorouracil plus cisplatin and radiation twice a day (FCT) is an established chemoradiation (CRT) regimen for selective bladder-sparing treatment of muscle-invasive bladder cancer. Gemcitabine and once daily radiation (GD) is a well-supported alternative. The current trial evaluates these regimens. METHODS: Patients with cT2-4a muscle-invasive bladder cancer were randomly assigned to FCT or GD. Patients underwent transurethral resection and induction CRT to 40 Gy...
November 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30433851/out-of-the-mouths-of-babes-a-physician-discusses-her-cancer-diagnosis-with-her-two-young-children
#6
Heather A Thompson Buum
No abstract text is available yet for this article.
November 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30433850/personalizing-medicine
#7
Timothy Gilligan
No abstract text is available yet for this article.
November 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30433849/reply-to-j-schildmann-et-al
#8
Fay J Hlubocky, Christopher K Daugherty
No abstract text is available yet for this article.
November 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30433848/validation-of-mayo-clinic-staging-system-for-light-chain-amyloidosis-with-high-sensitivity-troponin
#9
Shaji K Kumar, Morie A Gertz, Angela Dispenzieri
No abstract text is available yet for this article.
November 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30433847/informed-consent-and-phase-i-trials-cognitive-failure-and-additional-challenges-to-informed-decision-making
#10
Jan Schildmann, Florian Bruns
No abstract text is available yet for this article.
November 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30422741/evidence-based-criteria-for-tyrosine-kinase-inhibitor-interruption-in-pregnancy
#11
Nuno Cerveira, António Almeida
No abstract text is available yet for this article.
November 13, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30422740/optimizing-cardiovascular-care-in-children-with-acute-myeloid-leukemia-to-improve-cancer-related-outcomes
#12
Saro H Armenian, Matthew J Ehrhardt
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
November 13, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30422739/reply-to-n-cerveira-et-al
#13
Ellin Berman, Brian J Druker, Richard Burwick
No abstract text is available yet for this article.
November 13, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30407898/reply-to-v-turan-et-al
#14
Matteo Lambertini, Ann H Partridge, Lucia Del Mastro
No abstract text is available yet for this article.
November 8, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30407897/utility-of-gonadotropin-releasing-hormone-agonists-for-fertility-preservation-lack-of-biologic-basis-and-the-need-to-prioritize-proven-methods
#15
Volkan Turan, Giuliano Bedoschi, Kenny Rodriguez-Wallberg, Murat Sonmezer, Fernanda Silva Pacheco, Ozgur Oktem, Hugh Taylor, Kutluk Oktay
No abstract text is available yet for this article.
November 8, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30407896/reply-to-v-turan-et-al
#16
Zeev Blumenfeld
No abstract text is available yet for this article.
November 8, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30407895/long-term-survival-of-patients-with-melanoma-with-active-brain-metastases-treated-with-pembrolizumab-on-a-phase-ii-trial
#17
Harriet M Kluger, Veronica Chiang, Amit Mahajan, Christopher R Zito, Mario Sznol, Thuy Tran, Sarah A Weiss, Justine V Cohen, James Yu, Upendra Hegde, Elizabeth Perrotti, Gail Anderson, Amanda Ralabate, Yuval Kluger, Wei Wei, Sarah B Goldberg, Lucia B Jilaveanu
PURPOSE: Pembrolizumab is active in melanoma, but activity in patients with untreated brain metastasis is less established. We present long-term follow-up of pembrolizumab-treated patients with new or progressing brain metastases treated on a phase II clinical trial ( ClinicalTrials.gov identifier: NCT02085070). PATIENTS AND METHODS: We enrolled 23 patients with melanoma with one or more asymptomatic, untreated 5- to 20-mm brain metastasis not requiring corticosteroids; 70% of patients had prior systemic therapy...
November 8, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30407894/conceptualizing-de-implementation-in-cancer-care-delivery
#18
Wynne E Norton, David A Chambers, Barnett S Kramer
No abstract text is available yet for this article.
November 8, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30403573/role-of-donor-clonal-hematopoiesis-in-allogeneic-hematopoietic-stem-cell-transplantation
#19
Mareike Frick, Willy Chan, Christopher Maximilian Arends, Raphael Hablesreiter, Adriane Halik, Michael Heuser, David Michonneau, Olga Blau, Kaja Hoyer, Friederike Christen, Joel Galan-Sousa, Daniel Noerenberg, Verena Wais, Michael Stadler, Kenichi Yoshida, Johannes Schetelig, Esther Schuler, Felicitas Thol, Emmanuelle Clappier, Maximilian Christopeit, Francis Ayuk, Martin Bornhäuser, Igor Wolfgang Blau, Seishi Ogawa, Tomasz Zemojtel, Armin Gerbitz, Eva M Wagner, Bernd M Spriewald, Hubert Schrezenmeier, Florian Kuchenbauer, Guido Kobbe, Markus Wiesneth, Michael Koldehoff, Gérard Socié, Nicolaus Kroeger, Lars Bullinger, Christian Thiede, Frederik Damm
PURPOSE: Clonal hematopoiesis of indeterminate potential (CHIP) occurs in the blood of approximately 20% of older persons. CHIP is linked to an increased risk of hematologic malignancies and of all-cause mortality; thus, the eligibility of stem-cell donors with CHIP is questionable. We comprehensively investigated how donor CHIP affects outcome of allogeneic hematopoietic stem-cell transplantation (HSCT). METHODS: We collected blood samples from 500 healthy, related HSCT donors (age ≥ 55 years) at the time of stem-cell donation for targeted sequencing with a 66-gene panel...
November 7, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30403572/neoadjuvant-chemo-radiotherapy-with-total-mesorectal-excision-only-is-not-sufficient-to-prevent-lateral-local-recurrence-in-enlarged-nodes-results-of-the-multicenter-lateral-node-study-of-patients-with-low-ct3-4-rectal-cancer
#20
Atsushi Ogura, Tsuyoshi Konishi, Chris Cunningham, Julio Garcia-Aguilar, Henrik Iversen, Shigeo Toda, In Kyu Lee, Hong Xiang Lee, Keisuke Uehara, Peter Lee, Hein Putter, Cornelis J H van de Velde, Geerard L Beets, Harm J T Rutten, Miranda Kusters
PURPOSE: Improvements in magnetic resonance imaging (MRI), total mesorectal excision (TME) surgery, and the use of (chemo)radiotherapy ([C]RT) have improved local control of rectal cancer; however, we have been unable to eradicate local recurrence (LR). Even in the face of TME and negative resection margins (R0), a significant proportion of patients with enlarged lateral lymph nodes (LLNs) suffer from lateral LR (LLR). Japanese studies suggest that the addition of an LLN dissection (LLND) could reduce LLR...
November 7, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"